Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, inNRG1fusion-positive cancers
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-pr02
Abstract: Background: NRG1 fusions are oncogenic drivers of various cancers including pancreatic and lung adenocarcinomas. NRG1 fusion proteins bind to HER3, leading to HER2/HER3 heterodimerization, increased downstream signaling, and tumor growth. MCLA-128 is a bispecific antibody… read more here.
Keywords: positive cancers; 128 bispecific; her2; antibody ... See more keywords